AUS
NZ
UK
CA
USA
IND
Healthcare
Significant Insider Investments Highlight Confidence in Biohaven's Growth
October 06, 2024 12:13 PM PDT| By Team Kalkine MediaHeadlines,Insider Buying Indicates Confidence,Notable Transactions Over the Past Year,High Insider Ownership Reflects Alignment with Shareholders,Vladimir Coric, the Chairman and CEO of Biohaven Ltd.,(NYSE:BHVN),recently acquired a significant amount...
Molecular Partners Set to Present Posters at the 2024 SITC Annual Meeting
October 04, 2024 06:12 AM PDT| By Team Kalkine MediaHighlights:,Molecular Partners AG will present proof-of-concept data for its novel CD3 Switch-DARPin at the 2024 SITC Annual Meeting.,The company will also showcase additional analyses from the Phase 1 study of MP0317, focusing on advanced solid tumo...
Summit Therapeutics Completes Enrollment in Its Phase III HARMONi Trial
October 04, 2024 06:09 AM PDT| By Team Kalkine MediaHighlights:,Summit Therapeutics has completed enrollment for the HARMONi Phase III clinical trial, evaluating ivonescimab in combination with platinum-doublet chemotherapy for EGFR-mutated non-small cell lung cancer (NSCLC) patients.,The FDA has gran...
Oncolytics Biotech® Highlights Key Developments and Future Studies in Cancer Treatments
October 04, 2024 05:57 AM PDT| By Team Kalkine MediaHighlights:,Oncolytics Biotech reports a median progression-free survival benefit of 5.7 months in the BRACELET-1 trial for HR+/HER2- breast cancer.,A Phase 2 study aimed at FDA accelerated approval is set to commence in the first half of 2025, focus...
_09_25_2024_14_24_01_892990.jpg)
Summit Therapeutics Completes Enrollment in HARMONi Trial for NSCLC Treatment
October 03, 2024 09:56 PM PDT| By Team Kalkine MediaKey Highlights,HARMONi Trial Enrollment: The trial successfully enrolled patients across North America, Europe, and China, marking a significant milestone in global clinical research.,FDA Fast Track Designation: The U.S. Food and Drug Administration...
.jpg)
Editas Medicine Secures $57 Million Through License Fee Sale
October 03, 2024 09:46 PM PDT| By Team Kalkine MediaHighlights,Editas has announced a financial transaction involving the sale of future license fees owed under its Cas9 license agreement with Vertex Pharmaceuticals.,Under the terms of the agreement, Editas Medicine is set to receive an upfront paymen...
Theriva Advances Clinical Trial with Positive Data
October 03, 2024 02:02 PM PDT| By Team Kalkine MediaHighlights,Theriva Biologics reported positive safety and pharmacokinetic data from the second cohort of its ongoing clinical trial for SYN-004, designed to prevent acute graft-versus-host disease in allogeneic hematopoietic cell transplant patients....
FDA Clears Key Hurdle for Eli Lilly's Blockbuster Drugs
October 03, 2024 01:18 PM PDT| By Team Kalkine MediaHighlights,The FDA has removed Eli Lilly’s popular weight-loss and diabetes drugs from its shortage list, reducing the market for compounded alternatives.,The removal follows efforts by Eli Lilly to increase supply, especially for Zepbound, as the co...
Navigating Change: Zimmer Biomet's Revised Analyst Ratings
October 03, 2024 12:38 PM PDT| By Team Kalkine MediaHeadlines,Zimmer Biomet experiences adjusted target prices from multiple research firms.,Analysts remain divided on the stock, reflecting various market perspectives.,Current consensus indicates cautious optimism for Zimmer Biomet's future performanc...
Zimmer Biomet’s Performance Reflects Resilience
October 03, 2024 12:27 PM PDT| By Team Kalkine MediaHighlights,Zimmer Biomet’s price-to-earnings ratio is higher than many peers, reflecting expectations of continued earnings growth and market outperformance.,The company has achieved strong earnings growth recently, which justifies the higher valuati...
Amgen's Institutional Influence and Strategic Direction
October 03, 2024 11:22 AM PDT| By Team Kalkine MediaHighlights:,Institutional investors have the majority of shares in Amgen, indicating significant influence over the company’s decisions and strategy.,Despite heavy institutional ownership, no single shareholder dominates Amgen, ensuring a diverse spr...
Elevance Health Sees Strong Institutional Backing as Investors Increase Stakes
October 03, 2024 09:49 AM PDT| By Team Kalkine MediaHeadlines,Major investors are increasing their involvement in Elevance Health, indicating confidence in the company's prospects.,Multiple investment firms have recently established new stakes in Elevance Health, reflecting growing interest in the fir...
Validation of Wound Measurement Technology Accomplished by Spectral AI Through Proof-of-Concept.
October 03, 2024 06:45 AM PDT| By Team Kalkine MediaHighlights:,Spectral AI completes a proof-of-concept module for its wound measurement technology, integrated into the DeepView System.,The technology provides fast and accurate total body surface area calculations for burn wounds, enhancing treatment...
Lumos Diagnostics Secures Funding from the US for FebriDx® Test and Regulatory Initiatives
October 03, 2024 05:27 AM PDT| By Team Kalkine MediaHighlights,Lumos Diagnostics Holdings Ltd secures nearly $3 million in non-dilutive funding from BARDA for its FebriDx® rapid diagnostic test.,The funding will support a clinical study for a CLIA waiver and FDA regulatory submission, aiming to expand...
Oncocyte Corporation (Nasdaq: OCX) Expands Market Presence with GraftAssure™ Agreements
October 03, 2024 04:36 AM PDT| By Team Kalkine MediaKey Highlights:,Oncocyte partners with top transplant hospitals in the U.S. and Germany for GraftAssure™.,The Company aims for FDA clearance for clinical use of its dd-cfDNA kitted test.,Strong demand for GraftAssure exceeds expectations, bolstered b...
Perspective Therapeutics Earnings Forecast: Analyst Insights
October 03, 2024 04:32 AM PDT| By Team Kalkine MediaHeadlines,Wedbush updates earnings projections for Perspective Therapeutics,Company shows slight earnings improvement despite losses,Multiple analysts offer positive outlook on stock performance,Wedbush,(NYSE:WFC),has recently provided insights into...
CVS Health Explores Splitting Retail and Insurance Divisions
October 01, 2024 11:02 AM PDT| By Team Kalkine MediaHighlights,CVS Health Corp's strategic review could lead to possible separation of its retail and insurance divisions.,Integration between Aetna and CVS has been a focus since the 2018 acquisition, improving healthcare services.,A potential breakup r...
Haleon’s Rating Reconfirmed After Changes in Pfizer's Stake
October 01, 2024 04:35 AM PDT| By Team Kalkine MediaHighlights,Pfizer Inc. has reduced its stake in Haleon PLC, leading to a significant share repurchase.,UBS has reaffirmed its positive rating on Haleon following this development.,Haleon plans to cancel half of the repurchased shares as part of its s...
Corporate Split Readiness Noted at CVS
October 01, 2024 03:33 AM PDT| By Team Kalkine MediaHighlights,Potential Split,: CVS Health Corp is considering separating its retail and insurance divisions, potentially creating two publicly traded entities.,Investor Pressure,: The move comes in response to investor concerns following a lowered 2024...
Pfizer (NYSE:PFE) announces sale of shares in Haleon to raise £2.7bn
September 30, 2024 08:16 PM PDT| By Team Kalkine MediaPfizer Inc. (NYSE:PFE) is set to raise approximately £2.7 billion ($3.6 billion) through the sale of shares in Haleon Plc, as the pharmaceutical giant continues to reduce its stake in the UK-based consumer health company. This move underscores Pfizer...
